China grants licence to Merck’s KEYTRUDA for stomach cancer treatment

By Thomson Reuters Jun 25, 2024 | 6:08 AM

BEIJING (Reuters) – China’s National Drug Administration has granted Merck’s KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.

Merck is known as MSD outside the United States and Canada.

(Reporting by Beijing newsroom; Editing by David Goodman)